ConductScience.org, home

Paper15530895

Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs.

Walter MF and 5 others. Atherosclerosis, 2004. Cited by 90 papers, by iCite.

Cite this record

ConductScience Library. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Papers, record 15530895. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/15530895

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs.
PubMed
Journal
Atherosclerosis
PubMed
Year
2004
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
90
iCite
Relative citation ratio, by iCite
2.41
iCite
Revised in PubMed
2026-01-28
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Walter MFMary F
2Jacob RFRobert F
3Day CACharles A
4Dahlborg RRachel
5Weng YYujia
6Mason RPR Preston

Source PubMed

Download CSV of authors

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cholesterol, LDLMajor topic
Cyclooxygenase InhibitorsMajor topic
LactonesMajor topic
PyrazolesMajor topic
SulfonamidesMajor topic
SulfonesMajor topic
Animals
Antioxidants
Celecoxib
Chromans
Diclofenac
Humans
Ibuprofen
Isoprostanes
Isoxazoles
Meloxicam
Naproxen
Oxidation-Reduction
Thiazines
Thiazoles
Benzenesulfonamides

Source PubMed

Download CSV of topics

Cited by27

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 90 citations.

PMIDTitleJournalYearIn PapersSource
38799798Imrecoxib: Advances in Pharmacology and Therapeutics.Drug Des Devel Ther2024https://conductscience.org/library/papers/38799798PubMed
37834442MicroRNA as Possible Mediators of the Synergistic Effect of Celecoxib and Glucosamine Sulfate in Human Osteoarthritic Chondrocyte Exposed to IL-1β.Int J Mol Sci2023https://conductscience.org/library/papers/37834442PubMed
35472207Development of stealth liposomal formulation of celecoxib: In vitro and in vivo evaluation.PLoS One2022https://conductscience.org/library/papers/35472207PubMed
34445685A Combination of Celecoxib and Glucosamine Sulfate Has Anti-Inflammatory and Chondroprotective Effects: Results from an In Vitro Study on Human Osteoarthritic Chondrocytes.Int J Mol Sci2021https://conductscience.org/library/papers/34445685PubMed
32821151Practice Advisory on the Appropriate Use of NSAIDs in Primary Care.J Pain Res2020https://conductscience.org/library/papers/32821151PubMed
30631366Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac.Int J Rheumatol2018https://conductscience.org/library/papers/30631366PubMed
30288088Nonsteroidal anti-inflammatory drugs in chronic pain: implications of new data for clinical practice.J Pain Res2018https://conductscience.org/library/papers/30288088PubMed
29020251
Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial.
Eur Heart J2017https://conductscience.org/library/papers/29020251PubMed
27747190Formulation and Evaluation of Liposomes for Transdermal Delivery of Celecoxib.Jundishapur J Nat Pharm Prod2015https://conductscience.org/library/papers/27747190PubMed
27104573Development of Antioxidant COX-2 Inhibitors as Radioprotective Agents for Radiation Therapy-A Hypothesis-Driven Review.Antioxidants (Basel)2016https://conductscience.org/library/papers/27104573PubMed
26022804Phenotyping drug polypharmacology via eicosanoid profiling of blood.J Lipid Res2015https://conductscience.org/library/papers/26022804PubMed
25342992Comparative evaluation of cardiovascular outcomes in patients with osteoarthritis and rheumatoid arthritis on recommended doses of nonsteroidal anti-inflammatory drugs.Ther Adv Musculoskelet Dis2014https://conductscience.org/library/papers/25342992PubMed
25199097Effects of repeated oral administration of pazufloxacin mesylate and meloxicam on the antioxidant status in rabbits.J Am Assoc Lab Anim Sci2014https://conductscience.org/library/papers/25199097PubMed
23749198The effects of cyclooxygenase and nitric oxide synthase inhibition on oxidative stress in isolated rat heart.Mol Cell Biochem2013https://conductscience.org/library/papers/23749198PubMed
23079497Design, synthesis and in vivo anti-inflammatory activities of 2,4-diaryl-5-4H-imidazolone derivatives.Molecules2012https://conductscience.org/library/papers/23079497PubMed
22187234Effects of combination therapy with celecoxib and doxycycline on neointimal hyperplasia and inflammatory biomarkers in coronary artery disease patients treated with bare metal stents.Yonsei Med J2012https://conductscience.org/library/papers/22187234PubMed
22084715Efficacy and Safety of COX-2 Inhibitors in the Clinical Management of Arthritis: Mini Review.ISRN Pharmacol2011https://conductscience.org/library/papers/22084715PubMed
19641861Cellular membranes function as a storage compartment for celecoxib.J Mol Med (Berl)2009https://conductscience.org/library/papers/19641861PubMed
18473007Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice?Ther Clin Risk Manag2007https://conductscience.org/library/papers/18473007PubMed
17393325The anti-cancer effect of COX-2 inhibitors on gastric cancer cells.Dig Dis Sci2007https://conductscience.org/library/papers/17393325PubMed

See all 27 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
PTGS25743PubTator's text mininghttps://conductscience.org/library/genes/5743

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/15530895

GET https://conductscience.org/api/papers/v1/15530895/cited_by?page=2